All Interventions

    Hormone Replacement Therapy (Female)

    Hormones
    Estrogen/Progesterone

    Restoration of estrogen, progesterone, and sometimes testosterone in peri/postmenopausal women to alleviate symptoms and support long-term health.

    Evidence Summary

    8
    / 10Score
    Strong
    Good Clinical Evidence

    Menopausal hormone therapy (MHT) has been substantially reappraised since the early-2000s Women's Health Initiative (WHI) scare. In the WHI's 18-year cumulative follow-up (Manson et al., JAMA 2017; 27,347 women), all-cause mortality for pooled estrogen±progestin therapy trended lower when therapy was started earlier in life — hazard ratio 0.89 (95% CI 0.79–1.01) for women who began at age 50–59, versus 0.98 (0.91–1.05) at 60–69 and 1.03 (0.96–1.10) at 70–79 — although this age trend did not reach statistical significance (P=0.06). This pattern underpins the widely accepted 'timing hypothesis': benefits are most favorable, and risks lowest, when MHT is initiated before age 60 or within 10 years of menopause. A Cochrane systematic review (Boardman et al., 2015) similarly found lower all-cause mortality in this early-initiation group (relative risk 0.70, 95% CI 0.52–0.95). For symptom control the evidence is unambiguous: systemic estrogen is the most effective treatment for moderate-to-severe vasomotor symptoms, and MHT reduces hip and vertebral fracture risk (WHI hip-fracture hazard ratio ≈0.66 for estrogen+progestin). Breast-cancer signals differ by regimen: estrogen-plus-progestin showed a modest long-term increase in invasive breast cancer (hazard ratio ≈1.28), whereas estrogen-alone (in women with prior hysterectomy) was associated with a lower incidence (hazard ratio ≈0.78) — an important distinction for individualized counseling. Reflecting this reappraisal, in November 2025 the U.S. FDA removed the decades-old boxed ('black box') warning from systemic menopausal hormone therapy products, and 2025 guidance from the International Menopause Society and the European Society of Endocrinology reaffirms MHT as first-line therapy for vasomotor symptoms and for bone protection in appropriately selected women. Therapy should remain individualized to each woman's symptoms, age, time since menopause, and personal risk profile. This is educational information, not medical advice.

    Evidence Scale

    1
    2
    3
    4
    5
    6
    7
    8
    9
    10
    AnecdotalStrong RCT

    Mechanism of Action

    Replaces declining ovarian hormones. Estrogen supports vasomotor function, bone density, cardiovascular health, and cognition. Progesterone balances estrogen and supports sleep.

    Who Is This For?

    Symptomatic menopause, early menopause, surgical menopause, osteoporosis prevention. Must weigh individual risk factors.

    Protocol & Dosing

    Dose

    Estradiol 0.5-2mg transdermal, Progesterone 100-200mg oral at bedtime. Testosterone 0.5-2mg as needed.

    Frequency

    Daily

    Duration

    Ongoing with annual reassessment

    Protocol Summary

    Bioidentical estradiol + progesterone preferred. Various routes: transdermal, oral, vaginal. Individualized dosing.

    Human RCT Follow-up · WHI 18-year

    All-cause mortality by age at initiation: the timing hypothesis

    Pooled estrogen±progestin therapy vs placebo; hazard ratios below 1.0 favor therapy. The gradient toward lower mortality with earlier initiation supports the 'timing hypothesis', though the age trend was not statistically significant (P=0.06). Source: Women's Health Initiative 18-year cumulative follow-up, Manson et al., JAMA 2017;318(10):927–938.

    Latest Evidence

    The modern reappraisal of menopausal hormone therapy centers on timing: initiated before age 60 or within 10 years of menopause, MHT is the most effective treatment for vasomotor symptoms and supports bone health, with a reassuring long-term profile. In November 2025 the FDA removed the decades-old boxed warning from systemic MHT products.

    Interactions & Precautions

    Contraindications

    • Breast cancer history
    • Active thromboembolism
    • Unexplained vaginal bleeding
    • Active liver disease

    Potential Risks

    • •Breast cancer risk (debated)
    • •Thromboembolism
    • •Gallbladder disease

    Potential Side Effects

    Breast tenderness
    Bloating
    Headaches
    Mood changes during adjustment

    Practitioner Notes

    Clinical annotations from Dr. Goel

    Transdermal estradiol avoids first-pass liver effects. Start within 10 years of menopause for best outcomes. Oral micronized progesterone for endometrial protection. Updated August 16, 2026 (context, not a change in recommendation): Nature Aging 2026 (Carleton et al.) profiled age-associated differences in ER-positive breast cancer using an aged rat model, human patient tissue and patient-derived organoids, and found that systemic and local chronic inflammation together with altered ENDOGENOUS estrogen disposition create a tumour-permissive breast microenvironment in older women. Read this carefully before it reaches patients in distorted form: the study concerns host aging biology and endogenous hormone metabolism, it tested no exogenous hormone therapy, and it says nothing about whether menopausal hormone therapy raises or lowers this risk. It does not alter HRT risk-benefit counselling, which should continue to rest on the randomised and observational literature already summarised above. Its practical value is as a reminder that inflammatory and metabolic status in older women is part of the breast-cancer risk conversation independent of hormone exposure. Updated October 15, 2026: In November 2025 the U.S. FDA removed the long-standing boxed warning from systemic menopausal hormone therapy products. Counsel on the timing hypothesis (best initiated before age 60 or within 10 years of menopause) and on regimen-specific breast-cancer considerations (estrogen-plus-progestin vs estrogen-alone). Prefer transdermal estradiol to reduce venous thromboembolism risk; ensure endometrial protection with progestogen in women with a uterus.
    SG

    Dr. Sanjeev Goel

    Chief Medical Officer, Peak Human

    Cost & Access

    Cost Range

    $$

    Accessibility

    Widely available

    Availability varies by location

    PHS
    671
    / 1000
    T3
    Longevity Operator

    Sample member

    Longevity Operator

    The Peak Human Score · PHS v1

    One number for your longevity journey.

    FICO for credit. PHS for longevity. Eight biological domains collapsed into one provable score — intuitive at a glance, rigorous underneath.

    • Metabolic
    • Hormonal
    • Cardiovascular
    • Brain / Cognitive
    • Sleep
    • Musculoskeletal
    • Gut
    • Immunity / Inflammation